Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.

Mayo Clinic proceedings·2026
Same author

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia.

Blood cancer journal·2026
Same author

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Future oncology (London, England)·2026
Same author

Multi-omics analysis reveals a unique epigenetic signature in <i>MYD88</i> wild-type Waldenström macroglobulinemia.

Haematologica·2025
Same author

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Med (New York, N.Y.)·2025
Same author

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia.

Journal of managed care & specialty pharmacy·2025

Related Experiment Video

Updated: Sep 1, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.8K

CD38 as a multifaceted immunotherapeutic target in CLL.

Aneel Paulus1,2, Fabio Malavasi3,4, Asher Chanan-Khan1,2

  • 1Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.

Leukemia & Lymphoma
|August 17, 2022
PubMed
Summary

This review explores the role of CD38 in chronic lymphocytic leukemia (CLL). It examines how targeting CD38 offers therapeutic benefits and novel treatment strategies for CLL patients.

Keywords:
CD38CLLimmunotherapeutic target

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

Related Experiment Videos

Last Updated: Sep 1, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

12.8K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • CD38 is a protein found on chronic lymphocytic leukemia (CLL) cells.
  • Elevated CD38 levels in CLL correlate with poor prognosis and reduced survival.
  • CD38 influences B-cell receptor signaling and nicotinamide adenine dinucleotide metabolism.

Purpose of the Study:

  • To elucidate the dual role of CD38 in CLL pathogenesis, encompassing its enzymatic and receptor functions.
  • To review the therapeutic potential of inhibiting CD38 in CLL.
  • To explore novel immunotherapeutic strategies targeting CD38.

Main Methods:

  • Review of existing literature on CD38's function and prognostic value in CLL.
  • Analysis of data from studies involving anti-CD38 therapies.
  • Examination of mechanisms underlying CD38-mediated CLL cell death.

Main Results:

  • CD38's enzymatic and receptor functions significantly contribute to CLL progression.
  • High-affinity anti-CD38 drugs reveal critical functions detrimental to CLL cell survival.
  • Understanding these functions facilitates the development of targeted immunotherapies.

Conclusions:

  • CD38 is a key driver of CLL pathogenesis.
  • Targeting CD38 presents a promising therapeutic avenue for CLL.
  • Further research into novel CD38-targeting strategies is warranted.